explore -WSS

explore

author：hotspot 2025-09-28 09:17:25 - browse：47

Joe Biden in 2016. -- first opinion coverage from STAT — President Joe Biden Elise Amendola/AP

WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few questions on how Congress might move forward with the program.

Since its launch in 2016, the federally funded cancer moonshot program has spurred thousands of scientific publications, 49 clinical trials, and more than 30 patent filings, according to a new report from the Congressional Research Service, the nonpartisan research arm of Congress.

The next phase of the cancer moonshot, according to Biden and his administration, is meant to emphasize cancer screening, prevention, and equitable treatment. The updated plan also seeks to speed progress on treatments for rare and childhood cancers, and it calls for supporting patients, survivors, and caregivers. The Advanced Research Projects Agency for Health (ARPA-H), a new agency tasked with taking big risks on biomedical and health technology, is also committing $240 million to cancer-related research and investing in new data-sharing platforms and a nationwide network for clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Diagnostic tests are hitting their mathematical limits

focus

WSS

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Food makers tried to stack nutrition panel with preferred experts

PEPFAR is under serious threat — and so is global health

Acelyrin, a rare IPO success, stumbles in its first big test

Will the IRA bring competition to the biologics market?

Diverse clinical trials: Why aren’t we there yet?

focus

explore

knowledge

How one medical school became remarkably diverse

BIO selects John Crowley as new CEO

23andMe had bad news about my health. I wish a person had delivered it

BIO selects John Crowley as new CEO

How one medical school became remarkably diverse

FDA proposes changes to key medical devices approval pathway

Tori Bowie and the unacceptable rates of Black maternal death

U.K. Biobank has 500,000 peoples' genome sequences available

The cancer drug shortage isn’t new — and neither are the solutions

As biotech industry slumps, bioscience job market is upside down

focus

U.K. Biobank has 500,000 peoples' genome sequences available

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

FDA investigates CAR

What to make of Biden’s latest efforts on cancer research

Hospitals consider fixing cancer drug shortages on their own

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

focus

leisure time

explore

focus